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Abstract
Tissue inhibitors of metalloproteinases (TIMPs) regulate diverse processes, including extracellular
matrix (ECM) remodeling, and growth factors and their receptors' activities through the inhibition
of matrix metalloproteinases (MMPs). Recent evidence has shown that this family of four members
(TIMP-1 to TIMP-4) can also control other important processes, such as proliferation and
apoptosis, by a mechanism independent of their MMP inhibitory actions. Of these inhibitors, the
most recently identified and least studied is TIMP-4. Initially cloned in human and, later, in mouse,
TIMP-4 expression is restricted to heart, kidney, pancreas, colon, testes, brain and adipose tissue.
This restricted expression suggests specific and different physiological functions. The present
review summarizes the information available for this protein and also provides a putative structural
model in order to propose potential relevant directions toward solving its function and role in
diseases such as cancer.
Background
The extracellular matrix (ECM) not only maintains the
three-dimensional structure of tissues and organs, but also
plays critical roles in cell proliferation, differentiation,
survival and motility. Key to ECM remodeling are the
Matrix Metalloproteases (MMPs) and their inhibitors, the
Tissue Inhibitors of Metalloproteinases (TIMPs) [1]. These
proteins constitute a proteolytic system that participates
not only in the breakdown of ECM components and sub-
sequent tissue remodeling, but also provides an impor-
tant regulatory role in the microenvironment [2]. This is
accomplished by the ability of MMPs to modulate the
availability and activity of growth factors and cytokines or
their receptors, and to process adhesion and signaling
receptor targets [3]. For these reasons, it is not unexpected
that dysregulation of components of this system are com-
mon in diverse pathologies. In particular, it has been
found that overproduction of MMPs is associated with
cancer initiation and progression in diverse tissues [4].
Although there are several mechanisms that regulate MMP
expression, the ultimate control is achieved through inter-
action with the TIMPs. Intuitively, due to their inhibitory
actions, members of this family should be able to inhibit
cancer invasion and thus, be antitumoral proteins. Never-
theless, under some circumstances, specific MMPs have a
dual role in cancer, with antitumoral activities [1]. In
addition, recent evidence has shown that members of the
TIMP family can also control other important processes
such as proliferation and apoptosis by mechanism(s)
independent of their MMP inhibitory actions [5]. This
family is composed of four members with high sequence
homology and structural identity, but with different tissue
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expression, regulation and inhibitory characteristics. The
most recently identified and least studied member of this
family is TIMP-4. Initially cloned in human and later in
mouse, TIMP-4 expression is restricted to heart, kidney,
pancreas, colon, testes, brain and adipose tissue. This
restricted expression suggests specific and different physi-
ological functions.
Structure
Human TIMP-4 is a non-glycosylated, 195 amino acids
long polypeptide, the largest of the currently identified
human inhibitors of matrix metalloproteinases (MMP)
(Fig 1). TIMP-4 and TIMP-2 are 51% identical at the
amino acid level, with TIMP-4 only one residue larger
than TIMP-2. Contrastingly, TIMP-4 is eleven and seven
residues larger than TIMP-1 and TIMP-3 and shows 37%
and 51% identity to these proteins, respectively [6-9]
(Table 1). Distinctive within the TIMP family, TIMP-4 has
twelve Cys residues that form six conserved disulfide
bridges [8,10]. The three-dimensional (3D) structure of
TIMP-4 has not yet been determined, but due to the rela-
tive high sequence identity it shares with the other TIMPs,
in particular to TIMP-2, a high structural similarity to
those proteins could be expected [7]. The TIMPs fold into
two very distinct domains, a larger N-terminal domain
that carries the MMP inhibitory activity and a smaller C-
terminal domain that mediates other non-inhibitory
interactions, notably with some pro-MMP forms (Fig 2A)
[8,9,11-13]. The N-terminal domain encompasses nearly
two-thirds of the polypeptide chain and is reminiscent of
the oligonucleotide/oligosaccharide-binding (OB) fold
[14-19]. This motif was first described in proteins binding
oligonucleotides or oligossacharides [20] and is present in
twelve protein superfamilies within the SCOPE (Struc-
tural Classification of Proteins, http://scop.mrc-
lmb.cam.ac.uk/scop/) data base, including the staphylo-
coccal nucleases, bacterial enterotoxins, heme chaperone
CcmE, N-terminal domain of the tail-associated lysozyme
gp5 of bacteriophage T4, nucleic acid-binding proteins
and inorganic pyrophosphatases, among others [21,22].
The core of the TIMP OB region is formed by a five-
stranded anti-parallel β pleated sheet rolled into a β-bar-
rel, stabilized by three disulfide bonds. The strands form-
ing the barrel are connected by loops, which in some cases
differ in length from one TIMP to another. Three segments
folded in α-helices (α-helix 1 to 3) are associated with the
β-barrel core (Fig 2A) [8,12,14-18,23-26]. The N-terminal
domain can be expressed and folded independently and,
as it was pointed out above, is necessary and sufficient for
MMP inhibition [15,27-29].
The C-terminal domain folding topology is characterized
by a β-hairpin plus a β-loop-β motif with two associated
310-helices (Fig 2) [14,16,17,26]. Notably, this fold has
not been observed in other proteins different from the
TIMPs among the structures deposited at the Brookhaven
Protein Data Bank (http://www.rcsb.org/pdb/home/
home/.do).
Crystallographic structure analysis of the TIMPs in com-
plex with MMPs has shown that the long edge of the
wedged-shaped inhibitor occupies the entire length of the
MMP active-site cleft. A central part of this molecular edge
is formed by a short stretch of five relatively conserved res-
idues at the N-terminus that adopts an extended confor-
mation and a portion of the loop connecting the β-strands
C and D (CD-loop) (Fig 2B). The pentapeptide N-termi-
nal segment is connected to the core of the β-barrel by two
disulfide bridges involving Cys1-Cys70 and Cys3-Cys99
in TIMP-1. Continuing along this segment, the chain folds
helically (α-helix 1) and then proceeds into the proper β-
barrel motif at strand A (Fig 2) [14-16,19,23,25]. It has
been shown that the residues at the molecular edge criti-
cally contribute to defining the specificity and affinity of
the inhibitory binding to the MMPs. Mutational analysis
of Thr2 in TIMP-1 and Ser2 in TIMP-4 has shown that size,
charge and polarity of residue two in the TIMP structure is
a major determinant of MMP inhibition [16,23,27,29-
32].
From the alignment shown in Fig. 1, it is apparent that in
TIMP-4 the β-hairpin connecting the β-strands A and B
(AB-loop) differs in sequence and length relative to the
corresponding region in the other TIMPs. This loop is one
residue shorter than in TIMP-2 and six and five residues
larger than in TIMP-1 and TIMP-3, respectively. Crystallo-
graphic, NMR and site-directed mutagenesis studies have
revealed that the AB-loop is variably involved in the con-
tacts between TIMPs and MMPs [14-16,23]. It has been
shown that deleting this loop dramatically decreases the
rate of association and increases the equilibrium constant
Table 1: Sequence identity and similarity shown by human and 
non-human TIMPs compared to the human TIMP-4. 
Protein Identity
(%)
Similarity
(%)
hTIMP-1 37 57
hTIMP-2 51 70
hTIMP-3 51 70
paTIMP-4 100 -
muTIMP-4 91 95
raTIMP-4 92 96
boTIMP-4 90 96
tkTIMP-4 55 73
drTIMP* 21 43
The amino acid sequences analyzed are the same as shown in Fig. 1 
and the analysis was performed with BioEdit (Hall, T.A., 1999. BioEdit: 
a user-friendly biological sequence alignment editor and analysis 
program for Windows 95/98/NT.Nucl. Acids. Symp. Ser. 41:95–98).
* Drosophila melanogaster TIMP (gi 4157982)Molecular Cancer 2008, 7:85 http://www.molecular-cancer.com/content/7/1/85
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Figure 1 (see legend on next page)
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of TIMP-2 binding to the catalytic domain of MT1-MMP
(MMP-14) [33]. It was demonstrated that Tyr36, which is
unique within the TIMP-2 sequence and located at the tip
of the AB-loop, critically contributes to the interactions
with MT1-MMP [34]. Notably, the deletion of the AB-loop
in TIMP-4 exerts a considerably smaller effect in the kinet-
ics and thermodynamic of binding with MT1-MMP, sug-
gesting a different contribution of the TIMP-4 AB-loop for
the MT1-MMP binding [33]. TIMP-4, which associates
with the catalytic domain of MT1-MMP at a 20-fold
slower rate than TIMP-2, has Ala instead of Tyr at position
36. Moreover, TIMP-4 has two Pro residues at positions
relevant for the AB-loop that are not present in the other
TIMPs. Pro30 is located at the beginning and Pro35 at the
tip of the AB loop. In addition, Pro39 distinguishes the
AB-loop of TIMP-2 and TIMP-3 but is substituted for Thr
in TIMP-4 (Fig 1). These characteristics of the TIMP-4 AB-
loop sequence, that presumably induce local differences
respecting to TIMP-2 AB-loop, could also be of relevance
for MT1-MMP binding. Remarkably, it was shown that
grafting the entire TIMP-2 AB-loop to TIMP-4 transfers the
MT1-MMP binding functionality of TIMP-2 AB-loop to
TIMP-4. Improvement in the MT1-MMP-binding capacity
was also observed when the three residues located at the
tip of the TIMP-2 AB-loop, including Tyr36, were trans-
ferred to TIMP-4 (Fig. 1). It is of note that in both cases,
Pro30 and Pro35 in TIMP-4 were replaced by the corre-
sponding residues in TIMP-2 [33].
It is known that TIMP-4 binds to pro-MMP-2 as TIMP-2
does and is also a strong inhibitor of MT1-MMP; however,
notwithstanding the sequence similarity between both
inhibitors, TIMP-4 is unable to promote the activation of
the pro-MMP-2 by free MT1-MMP enzyme [35]. This
action is uniquely facilitated by TIMP-2 and is proposed
to require the formation of a membrane ternary complex
that includes TIMP-2, pro-MMP-2 and MT1-MMP [36-
38]. The crystallographic study of the complex formed by
TIMP-2 and pro-MMP-2 has shown that it involves the
interaction of the C-terminal domain of the inhibitor with
the hemopexin-like domain of the zymogen [17].
Sequence differences at the C-terminal domain between
TIMP-4 and TIMP-2 have been suggested to be the cause
of the inability of TIMP-4 to promote the activation of
pro-MMP-2. TIMP-4 lacks the Met149, Glu192 and
Asp193 residues that have been proposed to be key in sta-
bilizing the interactions of the C-terminal domain of
TIMP-2 with the hemopexin-like domain of pro-MMP-2.
In TIMP-4, Glu192 and Asp193 are replaced by Val and
Gln, respectively. In addition, Met149, around which the
main cluster of hydrophobic interactions between TIMP-
2 and pro-MMP-2 focuses, is replaced in TIMP-4 by Thr. In
support of this suggestion, it was recently demonstrated
that, in clear contrast with TIMP-2, TIMP-4 is unable to
form in vitro a stable complex with pro-MMP-2 in pres-
ence of the active form of MT1-MMP [33].
At present, six non-human TIMP-4 sequences, five of
them from mammals, have been reported [39-42] (Fig 1).
Those of mammalian origin are 90 to 100% identical to
hTIMP-4, with the chimpanzee TIMP-4 (paTIMP-4) the
most closely related. In contrast, the TIMP-4 of the fish
Takifugu rubripes (tkTIMP-4) shows only 55% identity to
hTIMP-4 [42], a value that compares with the similarity
between hTIMP-2 and hTIMP-4. Interestingly, tkTIMP-4
and hTIMP-2 are 50% identical at the sequence level,
which is in agreement with the proposed hypothesis of a
relatively close common ancestor for both TIMP-2 and
TIMP-4 (Fig 1 and Table 1) [8,42,43].
Regulation
Although the four members of the TIMP family are very
similar in structure, they present marked differences in
their expression pattern. While TIMP-2 expression is con-
stitutive and ubiquitous, TIMP-1, -3 and -4 expression is
inducible and tissue specific. TIMP-1 is mainly expressed
in the reproductive system; TIMP-3 in the heart, kidney,
and thymus, and TIMP-4 in heart, kidney, pancreas,
colon, testes, brain and adipose tissue [7]. TIMP genes
have been found in species ranging from Caenorhabditis
elegans to humans, suggesting a important and conserved
role in metazoans [8]. Interestingly, TIMP-1, 3 and 4 genes
are nested within introns of the synapsin gene family [44].
Since synapsins are neuronal-specific phosphoproteins
Comparison of the amino acid sequence of the human TIMP-4 (hTIMP-4) with those of the other human TIMPs (hTIMP-1,  hTIMP-2, and hTIMP3) and TIMP-4 from Pan troglodytes (paTIMP-4) Mus musculus (muTIMP-4), Rattus norvegicus (raTIMP-4),  Bos taurus (boTIMP-4), and Takifugus rubripes (tkTIMP-4) Figure 1 (see previous page)
Comparison of the amino acid sequence of the human TIMP-4 (hTIMP-4) with those of the other human 
TIMPs (hTIMP-1, hTIMP-2, and hTIMP3) and TIMP-4 from Pan troglodytes (paTIMP-4) Mus musculus (muT-
IMP-4), Rattus norvegicus (raTIMP-4), Bos taurus (boTIMP-4), and Takifugus rubripes (tkTIMP-4). The residues 
that differ from those encoded by hTIMP-4 are indicated. The secondary structure elements are aligned with the amino acid 
sequence of the TIMPs and labeled (H and β mean "helix" and "β-strand", respectively). The following amino acid sequences 
were used in the alignment (The GenInfo Identifier numbers, gi, are shown in parentheses): hTIMP-1 (49456917), hTIMP-2 
(4507511), hTIMP-3 (47678717), hTIMP-4 (3493223), paTIMP-4 (55619817), muTIMP-4 (110625888), raTIMP-4 (160370007), 
boTIMP-4 (109886638), tkTIMP-4 (29611415). The alignment was performed with ClustalX (Thompson, J.D., Gibson, T.J., 
Plewniak, F., Jeanmougin, F. and Higgins, D.G. 1997. The ClustalX windows interface: flexible strategies for multiple sequence 
alignment aided by quality analysis tools. Nucleic Acids Research, 24:4876–4882).Molecular Cancer 2008, 7:85 http://www.molecular-cancer.com/content/7/1/85
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Cartoon representation of the crystallography structure of the human TIMP-2 in uncomplexed state (A) and the bovine TIMP- 2 complexed with the catalytic domain on the metalloproteinase 13 (cdMMP-13) (B) Figure 2
Cartoon representation of the crystallography structure of the human TIMP-2 in uncomplexed state (A) and 
the bovine TIMP-2 complexed with the catalytic domain on the metalloproteinase 13 (cdMMP-13) (B). The 
regions of TIMP-2 folded as helices and β-strands are colored in red and yellow, respectively. The six conserved disulfide 
bridges characterizing the TIMP structure are shown in blue in figure A. In B, the cdMMP-13 is colored in blue and the catalytic 
Zn is colored in magenta and shown in space-filled format. The residues Cys1, Ser2 and Cys3 that form the core of the molec-
ular edge of the inhibitor that occupies the active-site cleft of the MMP, and the Cys72 and Cys101 are shown in stick format 
and colored yellow. The figure was prepared using PyMOL® and the coordinates of PDB 1BR9 (Fig. 2A) and PDB 2E2D (Fig. 
2B).Molecular Cancer 2008, 7:85 http://www.molecular-cancer.com/content/7/1/85
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involved in synaptogenesis and neurotransmitter release,
it is possible that TIMPs could have a regulatory role in the
brain. Characterization of mouse TIMP-4 promoter
showed potential sites for myogenin, GATA and Ets family
members. Interestingly, it lacks AP1 or AP2 sites, which
are involved in the inducible and basal expression of
TIMP-1, -2 and -3 genes [45]. Additionally, the TIMP-4
promoter contains an estrogen response element (ERE),
in accordance with the observed regulation by estrogen
during endometrial normal cycle and preimplantation
period [46,47]. Similar to TIMP-3, TIMP-4 expression is
regulated by promoter methylation in cancer cell lines
and tumor samples [48]. In addition, a polymorphism in
the region that transcribes the 3' UTR of the TIMP-4 has
been identified. The effect of this polymorphism on
TIMP-4 expression and function is unknown, however it
is associated with a major risk for osteoarthritis in the
Korean population [49]. TIMP-4 function is also regulated
by postranslational modifications. Peroxinitrite-induced
nitration and oligomerization impairs the inhibitory
effects of this protein on MMP-2. In this case, four tyrosine
residues on TIMP-4 are modified by peroxynitrite expo-
sure. Since peroxynitrite, via post-translational modifica-
tions of target proteins, contributes to cardiovascular
injury and cancer, its effect on TIMP-4 could be involved
in the pathology of these diseases [50].
Cellular functions
The most widely studied function of TIMPs is their inhibi-
tion properties on MMPs. Members of the MMP family
include the classical MMPs, the membrane-bound MMPs
(MT-MMPs), the ADAMs (a disintegrin and metallopro-
teinase) and the ADAMTS (a disintegrin and metallopro-
teinase with thrombospodin motif) [51]. These enzymes
and their specific inhibitors are involved in tumor pro-
gression and metastasis by regulating extracellular matrix
degradation [4]. As mentioned above, TIMP-4 is more
closely related to TIMP-2 and -3, than to TIMP-1. Accord-
ingly, the catalytic domain of MMP-19 can be inhibited by
TIMP-2, -3 and -4, while TIMP-1 is less efficient [52]
(Table 2). Additionally, MMP-26 is inhibited by the same
group of TIMPs, and the co-expression of these proteins
has been observed in endometrial carcinoma [53] and in
breast ductal carcinoma in situ (DCIS) [54]. Enzymatic
kinetics studies revealed IC50 values of 19, 3, 45, 8, 83,
and 0.4 nM for MMP-1, MMP-2, MMP-3, MMP-7, MMP-9
and MMP-26, respectively, thus demonstrating that TIMP-
4 has highest affinity for MMP-26 among these MMPs
[55-57] (Table 2). A special case is TIMP-2, which is the
only member of the family able to both inhibit and acti-
vate MMPs. Although TIMP-4 is able to form a complex
with MT1-MMP and the hemopexin domain of MMP-2, it
cannot activate the metalloproteinase. However, TIMP-4
can regulate the activity of MMP-2 by efficient inhibition
Table 2: Inhibitory activity of TIMP-4 on matrix metalloproteinases.
TIMP-4 Target MMP Kinetic parameter Key Residue(s) Ref.
full-length cdMMP-11 Ki 2.59 nM ? [57]
full-lenght cdMMP-11 IC50 19 nM ? [55]
full-lenght MMP-1 Ki 0.65 nM ? [57]
N-TIMP-42 MMP-2 Ki
app 0.3 nM ? [33]
full-lenght MMP-2 Ki
app ≤ 9 pM ? [35]
full-lenght MMP-2 IC50 3 nM ? [55]
full-lenght cdMMP-31 Ki 1.24 nM ? [57]
full-lenght MMP-3 IC50 45 nM ? [55]
full-lenght MMP-3 Ki 1.51 nM ? [57]
full-lenght MMP-7 IC50 8 nM ? [55]
N-TIMP-4 cdMMP-81 Ki 9.7 nM Ser2 [32]
N-TIMP-4 cdMMP-91 Ki 14.5 nM Ser2 [32]
full-lenght MMP-9 IC50 83 nM ? [55]
full-lenght MMP-26 IC50 0.4 nM ? [56]
N-TIMP-4 mbMT1-MMP3 Ki
app 1.0 nM ? [33]
full-lenght sMT1-MMP3 Ki
app 0.1 nM ? [35]
N-TIMP-4 ADAM-17/TACE Ki 8.68 nM ? [65]
full-lenght ADAM-17/TACE Ki 180 nM ? [65]
full-lenght cdADAM331 Ki 220 nM ? [62]
The table shows the kinetic parameter of the TIMP-4 target matrix metalloproteinase (MMP) and, when available, the key residue involved in the 
interaction.
1 Catalytic domain of the metalloproteinase.
2 Amino-terminal domain of TIMP-4.
3 mbMT1-MMP and sMT1-MMP refer to membrane-bond and soluble forms of Membrane Type 1 Matrix Metalloproteinase, respectively.
Ki = Inhibitory constant; IC50 = Median inhibitory constant; Ki
app = Apparent inhibitory constant. ? = not studied.Molecular Cancer 2008, 7:85 http://www.molecular-cancer.com/content/7/1/85
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of MT1-MMP-mediated activation and by inhibiting the
activated enzyme [35,58,59].
TIMPs can also inhibit members of the ADAM and
ADAMTS families. ADAMTSs are structurally and evolu-
tionarily more related to the ADAM family, and more dis-
tantly to MMPs [60]. TIMP-4 and -3 can inhibit the
proteolytic activity of ADAM28 on insulin-like growth fac-
tor binding protein-3 (IGFBP-3) [61]. Protease activity of
ADAM33 is also inhibited moderately by TIMP-3 and -4
and weakly inhibited by TIMP-2 but not by TIMP-1 [62].
In contrast, proteolytic activity of ADAM10 on myelin
basic protein can be inhibited by TIMP-1 and -3, while
TIMP-2 and -4 were unable to inhibit this activity [63].
TIMP-3 is also a good inhibitor of ADAM17, while TIMP-
2 and -4 are weak inhibitors, TIMP-1 did not show inhibi-
tion [64]. However a TIMP-4 mutant, in which three resi-
dues in the AB loop were replaced by surface residues of
TIMP-3, showed a ten-fold increase in the binding affinity
to ADAM17 [65]. For ADAMTS4, TIMP-3 is the most effi-
cient inhibitor, followed by TIMP-1 and -2, while TIMP-4
is a less efficient inhibitor [66]. ADAMTS2 is only inhib-
ited by TIMP-3, while TIMP-1, -2 and -4 did not show
inhibitory activity [67]. Although ADAMTS5 is inhibited
by TIMP-3, TIMP-4 is a weak inhibitor and no inhibition
by TIMP-1 and -2 was observed [68]. Platelets contain and
release several members of the TIMP, MMP and ADAM
families, including MMP-1, MMP-2, MMP-3, MMP-9,
MT1-MMP (MMP-14), ADAM10, ADAM17, ADAMTS13,
TIMP-1, TIMP-2 and TIMP-4. These proteins regulate
platelet functions such as agonist-stimulated platelet
adhesion and aggregation, tumor cell-induced platelet
aggregation and platelet-leukocyte aggregation [69].
TIMP-4 has been identified as the major MMP inhibitor in
human platelets [70], so it is possible that this protein has
an important regulatory role in these phenomena.
In addition to their inhibitory actions, TIMPs have inde-
pendent cell signaling functions that modulate angiogen-
esis, proliferation and apoptosis [71]. Mutants that lack
the ability to inhibit MMPs but retain the capacity to mod-
ulate specific cellular functions [72] have substantiated
the MMP-independent activities of both TIMP-1 and
TIMP-2. It has been shown that one of these mutants,
Thr2Gly-TIMP1, is able to protect MCF10A human breast
epithelial cell from apoptosis as efficiently as the wild type
TIMP-1 [71]. Similarly, a TIMP-2 mutant containing an
appending Ala residue at the amino terminus (Ala+TIMP-
2) binds the surface of human A549 cancer cells with high
affinity and retains an in vitro cell growth-inhibitory activ-
ity similar to the TIMP-2 wild type protein regardless of
being a non-active MMP-inhibitor [73]. Recently, a mayor
breakthrough in MMP-independent activities was
achieved by the discovery of binding partners for TIMP-1,
2 and 3 as CD63, integrin a3b1 and VEGF receptor-2,
respectively, and putatively CD63 for TIMP-4 [74].
Although not firmly established, the TIMP-4 association
could imply a similar role to that of TIMP-1, that is, the
ability to activate integrin b1 complex and promote sur-
vival signaling pathways such as FAK, Src, PI 3-K and
MAPK. TIMP-4 mutants that lack MMP-inhibitory activity
could be helpful in elucidating the MMP-dependence or
independence of normal and cancer cells' behavior [72].
This goal would be greatly facilitated by studies around
the structural basis of TIMP-4 MMP-inhibitory specificity.
TIMP-4 has proven to be difficult to fold efficiently in vitro
from bacterial inclusion bodies but it can be expressed in
mammalian cells [35], baculovirus [55], and yeast [32], in
a quantity that could facilitate the production of crystals
suitable for structural studies. For obvious reasons, deter-
mining the 3-D structure of free TIMP-4 as well as in com-
plex with relevant MMPs will be an important forward
step. Site-directed mutagenesis studies as well as the con-
struction of chimeras by domain-exchange could be help-
ful in identifying which region at the N- and/or C-
terminal domains of TIMP-4 are involved in binding to
the putative cellular receptor.
Role in cancer progression
Tumor microenvironment is key to cancer progression. To
survive and to achieve their full malignant phenotype,
cancer cells require signaling via adhesion molecules with
surrounding non-neoplastic cells, paracrine loops of
released signaling factors and extracellular matrix interac-
tion and degradation.
In particular, the extracellular matrix (ECM) presents not
only as a structural impediment to neoplastic cells' migra-
tion, but also contributes to their behavior by providing
biochemical clues such as growth factor and cytokines
that are anchored to it. Matrix metalloproteinases
(MMPs), a disintegrin and metalloproteinases (ADAMs)
and tissue inhibitors of metalloproteinases (TIMPs) con-
stitute the major proteolytic axis of ECM, and thus, are
critical for cancer progression.
For these reasons, it is not unexpected that TIMP-4 is dis-
regulated during cancer progression of several organs. Ele-
vated levels of TIMP-4 have been found in breast, ovary,
cervical, prostate, brain, colon, endometrium and papil-
lary renal tumors, whereas down-regulation was observed
in pancreatic and clear cell renal tumors (Table 3) [75-78].
This list is not comprehensive, since an expression profile
in the Oncomine database [79], which contains microar-
ray expression data for multiple cancer types, shows that
other cancer types also present up-regulated levels of
TIMP-4, including oligodendrogliomas and astrocytomas,
seminomas and hairy cell leukemias (Table 4).Molecular Cancer 2008, 7:85 http://www.molecular-cancer.com/content/7/1/85
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Interestingly, down-regulated levels were found in blad-
der, prostate and head and neck cancer. Three possible
reasons, not mutually exclusive, could explain these
opposing results. First, the methods used may account for
some of the results. Since it has been shown that there are
different TIMP-4 protein pools [80], mRNA expression
analyses may not accurately reflect protein levels at a par-
ticular time point. Second, disease or tissue-specific differ-
ences may account for some of the results. This is
exemplified by renal cell carcinoma, in which TIMP-4 is
elevated in papillary cancer cells, in contrast with clear cell
carcinoma, in which TIMP-4 mRNA is reduced [81].
Finally, temporal expressional changes during cancer pro-
gression could also explain the differences. Thus, analysis
of samples at later stages may detect only a TIMP-4
decrease, missing early changes, especially when the stud-
ies lack samples from initial cancer stages or normal tissue
controls. Supporting this scenario, it has been shown that
TIMP-4 increases in initial stages of prostate, breast and
glial tumors, decreasing at later stages (Table 3). A
decrease in expression at later stages has also been found
for pancreatic and endometrial tumors.
Clearly, additional studies using a wider range and
number of samples are needed to draw a conclusion, but,
for some tumors, a scenario in which TIMP-4 marks the
transition to invasive cancer emerges. This transition
seems also to be correlated with the expression of MMP-
26, a metalloproteinase inhibited by TIMP-4, providing
an important invasive proteolytic axis [54]. Since MMP-26
promotes invasion by dissolving basement membrane
after activation of MMP-9 [82], TIMP-4 may be acting as a
natural anti-invasive protein by preventing activation of
MMP-2 and 9, in a direct and indirect manner, as
described previously. This coexpression has been clearly
demonstrated in prostate [83], breast [54] and endome-
trial carcinomas [53], with the last two associated with the
estrogen receptor signaling pathway. Nevertheless, there
are two conflicting results. First, in contrast to early reports
on the antitumoral function of TIMP-4 on breast cancer
tumor growth and invasion [84], Jiang et al. reported that
systemic delivery of TIMP-4 stimulated breast cancer tum-
origenesis [85]. Although conclusive for the particular cell
line, this last report is not valid, since there is ample evi-
dence that the cell line used, MDA-435, is really a
melanoma line [86]. These results urgently call for a new
in vivo study. Second, Savinov et al. [87] have shown that
Table 3: TIMP-4 expression in human cancer. 
Cancer Assay Expression Reference
Breast IHC ↑ in early stages, ↓ in advanced stages [54]
Ovary IHC ↑ [78]
Cervical RT-PCR ↑ [77]
Prostate IHC ↑ in early stages, ↓ in advanced stages [83]
Gliomas RT-PCR ↑ in early stages, ↓ in advanced stages [76]
Pancreas IHC ↓ [75]
Colon IHC ↑ [80]
Endometrium IHC ↑ [46,53]
Kidney Papillary RT-PCR ↑ [81]
Kidney Clear cell RT-PCR ↓ [81]
Published research.
Up and down arrows represent increased and decreased expression, respectively
Table 4: TIMP-4 expression in human cancer. 
Cancer Differential expression # Studies P-value
Glioblastoma multiforme ↑ 2 1.2E-5 to 1.8E-17
Oligodendroglioma ↑ 2 1.5E-11 to 7.8E-17
Astrocytoma ↑ 2 5.3E-5 to 1.4E-16
Hairy cell leukemia ↑ 17 - 1 E - 8
Seminoma ↑ 1 3.1E-13
Bladder ↓ 2 2.2E-5 to 9.8E-8
Head and Neck ↓ 12 . 4 E - 7
Prostate ↓ 13 . 1 E - 7
Oncomine database.
Up and down arrows represent increased and decreased expression, respectively. P-value threshold was set to 1E-4Molecular Cancer 2008, 7:85 http://www.molecular-cancer.com/content/7/1/85
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MMP-26 up-regulation in breast ductal carcinoma in situ
correlates with longer patient survival, perhaps due to the
intracellular cleavage of ER-beta by this protease. These
authors later propose that the MMP-26 mislocalization
may be inhibiting cancer progression by its effects on ER-
beta [88]. Since TIMP-4 was not measured, no conclusion
regarding TIMP-4 correlation with breast cancer progres-
sion can be made, although further studies on the possi-
ble dual role of this inhibitor are warranted.
All these results point toward the need to perform addi-
tional studies to determinate the relevance of TIMP-4 in
cancer invasion and progression, in particular to establish
if a positive correlation with prognosis or inverse correla-
tion with invasion in patients can be made. In addition, in
light of the problems with previous models, the possible
use of TIMP-4 as a therapeutic target should not be dis-
missed. Finally, it is important to study the potential rele-
vance of the possible new transduction partners of TIMP-
4 on cancer progression and to identify the importance of
their localization.
Conclusion
Compared to other members of the family, TIMP-4 has
received less attention than deserved, perhaps due to the
restricted tissue expression and suspected pro-tumoral
activities. Nevertheless, the recent reports showing a cor-
relation between its expression and invasion and the
problems with the in vivo models warrant additional
efforts to establish the relevance of this protein in cancer.
In particular, additional studies are needed to elucidate its
molecular functions and intracellular role(s), analyze its
potential as a biomarker and to test if it could be a thera-
peutic target. These efforts surely will get TIMP-4 the atten-
tion it needs from the scientific community.
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